Clinical Trials
50 trialsLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Children's Oncology Group
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
St. Jude Children's Research Hospital
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Carboplatin and Bevacizumab for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
HUMC 1612: Optune NovoTTF-200A System
Hackensack Meridian Health
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
Massachusetts General Hospital
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
PETEY
Astellas Pharma Inc
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Astellas Pharma Inc
Everolimus for Children With Recurrent or Progressive Ependymoma
University of Texas Southwestern Medical Center
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
AXL1717
Rush University Medical Center
PIVOT IO 020
Bristol-Myers Squibb
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
National Institutes of Health Clinical Center (CC)
Antineoplaston Therapy in Treating Patients With Ependymoma
Burzynski Research Institute
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU Langone Health
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
M.D. Anderson Cancer Center
MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma
Massachusetts General Hospital
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Northwestern University
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
National Institutes of Health Clinical Center (CC)
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Pediatric Brain Tumor Consortium
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
NYU Langone Health
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
Stanford University
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Memorial Sloan Kettering Cancer Center
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
Case Comprehensive Cancer Center
A Study of Pemetrexed in Children With Recurrent Cancer
Eli Lilly and Company